Article
Genome-wide association analysis of treatment resistant schizophrenia for variant discovery and polygenic assessment.
Human genomics - 27 Sept 2024
Lenk Hasan Çağın, Koch Elise, O'Connell Kevin S, Smith Robert Løvsletten, Akkouh Ibrahim A, Djurovic Srdjan, Andreassen Ole A, Molden Espen
Abstract excerpt
BACKGROUND: Treatment resistant schizophrenia (TRS) is broadly defined as inadequate response to adequate treatment and is associated with a substantial increase in disease burden. Clozapine is the only approved treatment for TRS, showing superior clinical effect on overall symptomatology compared to other drugs, and is the prototype of atypical antipsychotics. Risperidone, another atypical antipsychotic with a...
Topics
Join the communities discussing this publication.